STOCK TITAN

Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Summit Therapeutics Inc. Co-Chief Executive Officer Mahkam Zanganeh, acting through the Mahkam Zanganeh Revocable Trust where she serves as trustee, bought 100,000 shares of common stock in an open-market purchase at $14.60 per share.

Following this transaction, that revocable trust held 25,824,474 shares of Summit Therapeutics common stock. Additional holdings reported include 31,000 shares held directly, 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust with her as trustee, 570,073,879 shares held by her spouse, and 76,680 shares held by an immediate family member. She disclaims beneficial ownership of these securities beyond any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Zanganeh Mahkam
Role Co-Chief Executive Officer
Bought 100,000 shs ($1.46M)
Type Security Shares Price Value
Purchase Common Stock 100,000 $14.60 $1.46M
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 25,824,474 shares (Indirect, By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee); Common Stock — 31,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Open-market purchase size 100,000 shares Common stock bought indirectly via revocable trust
Purchase price $14.60 per share Price for 100,000-share open-market purchase
Revocable trust holdings 25,824,474 shares Shares held by Mahkam Zanganeh Revocable Trust after transaction
Direct holdings 31,000 shares Shares held directly by Mahkam Zanganeh after transaction
Irrevocable trust holdings 10,199,776 shares Shares held by Shaun Zanganeh Irrevocable Trust
Spouse holdings 570,073,879 shares Shares reported as held by spouse
Immediate family holdings 76,680 shares Shares held by immediate family member
Net insider share change 100,000 shares Net buy according to transaction summary
open-market purchase financial
"100,000 shares of common stock in an open-market purchase at $14.60 per share"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
"the transaction was made indirectly through the Mahkam Zanganeh Revocable Trust"
Revocable Trust financial
"by the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
pecuniary interest financial
"disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein"
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zanganeh Mahkam

(Last)(First)(Middle)
C/O SUMMIT THERAPEUTICS INC.
601 BRICKELL KEY DRIVE, SUITE 1000

(Street)
MIAMI FLORIDA 33131

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Co-Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026P100,000A$14.625,824,474(1)IBy the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee
Common Stock76,680(1)IImmediate family member
Common Stock570,073,879(1)IBy Spouse
Common Stock10,199,776(1)IBy the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee
Common Stock31,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Remarks:
/s/ Mahkam Zanganeh06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SMMT Co-CEO Mahkam Zanganeh report?

Mahkam Zanganeh reported an open-market purchase of 100,000 Summit Therapeutics common shares at $14.60 each. The transaction was made indirectly through the Mahkam Zanganeh Revocable Trust, where she serves as trustee, and increased that trust’s reported holdings to 25,824,474 shares.

At what price did the Summit Therapeutics (SMMT) shares get purchased?

The reported insider purchase was executed at $14.60 per Summit Therapeutics common share. This price applies to the 100,000 shares acquired through the Mahkam Zanganeh Revocable Trust and is explicitly identified as an open-market purchase in the insider filing data.

How many SMMT shares does the Mahkam Zanganeh Revocable Trust hold after the trade?

After the reported transaction, the Mahkam Zanganeh Revocable Trust holds 25,824,474 Summit Therapeutics common shares. This figure represents the total number of shares attributed to that trust following the 100,000-share open-market purchase at $14.60 disclosed in the Form 4 data.

Does Mahkam Zanganeh claim full beneficial ownership of all reported SMMT shares?

No. The filing states she disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest, if any. This disclaimer applies to shares held through related trusts, her spouse, and an immediate family member cited in the ownership table.

What is the overall net effect of this Form 4 on SMMT insider positions?

The Form 4 reflects a net buy of 100,000 Summit Therapeutics shares, all from a single open-market purchase. Other line items update direct and indirect holdings, but the transaction summary shows no sales, gifts, or derivative exercises, only this one net purchase event.